CAR-NK Therapy for Lupus: A Cross-Domain Breakthrough from Tumor Immunotherapy to Autoimmune Disease

In recent years, chimeric antigen receptor (CAR) cell therapy has gradually expanded from oncology into autoimmune diseases. Among these, CAR-NK (chimeric antigen receptor natural killer cell) therapy is emerging as a new research hotspot in systemic lupus erythematosus (SLE).

As a disease driven by abnormal immune activation, lupus has long relied on glucocorticoids and immunosuppressants for management. However, high relapse rates and significant side effects mean there is still a substantial unmet clinical need. In this context, CAR-NK therapy offers a novel approach aimed at “resetting the immune system.”

Immunopathological Basis of Lupus

Systemic lupus erythematosus is a prototypical autoimmune disease characterized by a breakdown of immune tolerance. This leads to the production of large amounts of autoantibodies (such as anti-dsDNA antibodies), which form immune complexes that deposit in multiple organs (including the kidneys, skin, and joints), triggering chronic inflammation.

At the cellular level, abnormal activation of B cells is a key driving factor. These dysfunctional B cells not only continuously produce autoantibodies but also participate in antigen presentation and cytokine secretion, creating a vicious cycle. Therefore, targeting and eliminating pathogenic B cells has become a central therapeutic strategy in SLE, providing a clear entry point for CAR-based therapies.

What Is CAR-NK Therapy?

CAR-NK therapy involves genetically engineering natural killer (NK) cells to express chimeric antigen receptors (CARs), enabling them to recognize specific antigens and execute targeted cytotoxicity. Compared with CAR-T therapy, CAR-NK offers several potential advantages:

● Improved safety: Lower risk of cytokine release syndrome (CRS) and neurotoxicity

● “Off-the-shelf” potential: NK cells can be derived from donors or cell lines, enabling scalable manufacturing

● Stronger immunomodulatory capacity: NK cells not only kill target cells but also secrete cytokines that regulate the immune microenvironment

These characteristics make CAR-NK suitable not only for cancer treatment but also particularly promising for diseases involving immune dysregulation.

Mechanism of Action of CAR-NK in Lupus

In SLE, CAR-NK therapy primarily works by targeting B cells to achieve immune system “reconstruction.” The mechanism includes:

1.  Precise recognition of abnormal B cells

CARs are typically designed to target B-cell surface antigens such as CD19 or CD20, enabling CAR-NK cells to specifically identify pathogenic B-cell populations.

2.  Direct cytotoxic killing

CAR-NK cells release perforin and granzymes to rapidly induce apoptosis of target cells, thereby reducing the source of autoantibodies.

3.  Modulation of the immune microenvironment

NK cells secrete cytokines such as IFN-γ, which can suppress abnormal immune responses and help restore immune balance.

4.  Reduction of relapse risk

By eliminating pathogenic immune memory, CAR-NK therapy has the potential to reduce disease recurrence at its root.

This multi-dimensional mechanism suggests that CAR-NK therapy is not merely symptom-suppressing but may enable deeper disease intervention.

Advantages Compared with CAR-T Therapy

Although CAR-T therapy has shown initial success in autoimmune diseases, CAR-NK is demonstrating distinct advantages:

Overall, CAR-NK shows greater potential in safety and accessibility, making it particularly suitable for long-term management of chronic autoimmune diseases.

Clinical Progress and Research Status

Currently, CAR-NK therapy for lupus remains in early exploratory stages, but multiple studies have shown encouraging signals:

● In animal models, B-cell-targeting CAR-NK significantly reduces autoantibody levels

● Early clinical studies indicate improvements in immune biomarkers and disease activity

● Favorable safety profile, with no severe CRS or neurotoxicity observed

Meanwhile, researchers are exploring additional targets (such as BCMA) and optimizing CAR structures to enhance efficacy and persistence. These advances indicate that CAR-NK is transitioning from “proof of concept” toward “clinical feasibility.”

Future Directions

Looking ahead, the development of CAR-NK therapy for lupus may focus on:

● Multi-target CAR designs to better address complex immune dysregulation

● Enhanced persistence engineering, such as incorporating cytokine expression modules (e.g., IL-15)

● Combination strategies with biologics or immunomodulatory drugs

● Off-the-shelf product development to improve accessibility and reduce costs

With continued technological progress, CAR-NK may evolve from an experimental therapy into a routine clinical option.

Conclusion

CAR-NK therapy represents a new therapeutic paradigm—shifting from “immune suppression” to “immune reprogramming.” In the context of lupus, a complex autoimmune disease, it demonstrates the potential for a “functional cure” by precisely eliminating pathogenic B cells and restoring immune balance.

Although still at an early stage, ongoing technological advancements and accumulating clinical data suggest that CAR-NK could become a key pillar in the future treatment of autoimmune diseases, offering new hope to patients suffering from chronic inflammation and recurrent disease.

Based on a thorough understanding of client needs, Dengyue Pharma is committed to providing partners with one-stop pharmaceutical service solutions. From early-stage strategic planning to final implementation, professional teams offer comprehensive, end-to-end support throughout the entire process.